Sign in

GWPH on NASDAQ

GW Pharmaceuticals

Logo: https://www.gwpharm.com/ ( https://www.gwpharm.com/themes/custom/gwpharmglobal/logo.svg ), Non-free logo, via Wikipedia4

British pharmaceutics company

GW Pharmaceuticals Limited is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative to gain market approval in any country. Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018. It is a subsidiary of Jazz Pharmaceuticals.2 Its shares trade on NASDAQ under the symbol GWPH.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1998Founded1

Compare with another stock.

  • TickerGWPH on NASDAQ1
  • Industrybiotechnology, pharmaceutical industry1
  • HeadquartersPorton Down1
  • Websitewww.jazzpharmaceuticals.fr
  • Legal formprivate company limited by shares1
  • Listed onLondon Stock Exchange (GWP), Nasdaq (GWPH)1
  • LEI213800ISBN5CNUZMHZ393
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressSOVEREIGN HOUSE VISION PARK, CB24 9BZ Cambridge, United Kingdom3
  • Registered withCompanies House, 041609173

See how the biggest companies compare on our leaderboards

GW Pharmaceuticals Limited is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative to gain market approval in any country. Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018. It is a subsidiary of Jazz Pharmaceuticals.2

Corporate structure

GW Pharmaceuticals is part of a group headed by Jazz Pharmaceuticals. 22 entities, 8 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

  • Jazz Pharmaceuticals Ireland
    • GW Pharmaceuticals Cambridge, United Kingdom
      • GW PHARMA LIMITED Subsidiary · Cambridge, United Kingdom
      • GW RESEARCH LIMITED Subsidiary · Cambridge, United Kingdom
    • Jazz Pharmaceuticals (France) Subsidiary · Lyon, France
    • Chimerix, Inc. Subsidiary · Delaware, United States
    • Gentium S.r.l. Subsidiary · Italy
    • Jazz Capital Limited Subsidiary · Ireland
    • Jazz Financing Holdings Limited Subsidiary · Ireland
    • Jazz Financing I DAC Subsidiary · Ireland
    • Jazz Financing Lux S.à.r.l Subsidiary · Luxembourg
    • Jazz Investments Europe Limited Subsidiary · Malta
    • Jazz Investments I Limited Subsidiary · Bermuda
    • Jazz Pharmaceuticals (United States) Subsidiary · United States
    • Jazz Pharmaceuticals International Limited Subsidiary · Ireland
    • Jazz Pharmaceuticals Ireland Limited Subsidiary · Ireland
    • Jazz Pharmaceuticals Operations UK Limited Subsidiary · United Kingdom
    • Jazz Pharmaceuticals Research UK Limited Subsidiary · United Kingdom
    • Jazz Pharmaceuticals Therapeutics, Inc. Subsidiary · Delaware, United States
    • Jazz Pharmaceuticals UK Holdings Limited Subsidiary · United Kingdom
    • Jazz Pharmaceuticals UK Limited Subsidiary · United Kingdom
    • Jazz Securities DAC Subsidiary · Ireland

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

The story

GW Pharmaceuticals was founded in 1998 by doctors Geoffrey Guy and Brian Whittle. That year, they obtained a cultivation license from the United Kingdom Home Office and the MHRA, allowing the company to cultivate, possess and supply cannabis to conduct scientific research concerning medical cannabis.

Later in 1998, GW Pharmaceuticals entered into a contract with Hortapharm B.V., a cannabis research and development corporation based in Amsterdam.

In 2001, GW Pharmaceuticals listed on the Alternative Investment Market, the junior market of the London Stock Exchange. In May 2013, the company became dual-listed on the NASDAQ and AIM.

In 2014, the company made a deal with New York to develop clinical trials using cannabidiol (CBD) to treat children who suffer from seizures and other medical complications.

In May 2021, Jazz Pharmaceuticals acquired the company.

From Wikipedia’s article on GW Pharmaceuticals, shared under CC BY-SA 4.0.5

Products and brands

  • cannabidiol

Listed on Wikidata.1

Sativex

Nabiximols (trade name Sativex) is a botanical drug that is a cannabis extract, administered as a mouth spray; it was approved in the UK in 2010 as a treatment for multiple sclerosis (MS) patients to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms.

Nabiximols is made with two unknown Cannabis strains, and is extracted with ethanol and carbon dioxide.

In 2020, GW Pharmaceuticals concluded a partnership with Bayer for the distribution of Sativex in the UK. It has an estimated annual production of 100 tons of medicinal cannabis.

Epidiolex

In 2015, GW Pharmaceutical initiated Phase 3 clinical trials of cannabidiol oral solution for treatment of two rare diseases in children – Dravet syndrome and Lennox–Gastaut syndrome. In August 2015, GW received FDA Fast Track Development Program designation from the US Food and Drug Administration for use of the drug candidate to treat newborns with epilepsy.

Read the full text

The drug, under the brand name Epidiolex, was given US Food and Drug Administration approval in June 2018. It was subsequently given European EMA approval in September 2019 under the brand name Epidyolex.

From Wikipedia’s article on GW Pharmaceuticals, shared under CC BY-SA 4.0.5

Timeline

  1. 1998Founded Founded1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5